In this conversation Tanya Dorff and Alicia Morgans discuss the guidance coming from the NCCN on the use of radium-223 in the metastatic castration-resistant prostate cancer setting, including choosing the right patient for this drug, factors to consider, and the timing of this therapy. As lines of therapy become more complicated with many castration-resistant drugs moving to the…
Zach Klaassen and Ryan Malone discuss the management of Nonmetastatic castration-resistant prostate cancer (nmCRPC), focusing on the evolving role of PSMA PET imaging. They highlight…
Bladder cancer, external beam radiation therapy (EBRT), brachytherapy (BT), risk of bladder cancer after different prostate cancer treatment modalities, Secondary Bladder Cancers Following Prostate Cancer…
Prostate Cancer, Artificial Intelligence in prostate cancer treatment, Artificial Intelligence as a Digital Twin of Pathologists for Prostate Cancer, cribriform morphologies, prostate tissue stained with…
Zach Klaassen and Neal Shore discuss the outcomes of the EMBARK trial, focusing on treatment strategies for high-risk biochemically recurrent prostate cancer. In this detailed…
methods to convey PSMA-PET/CT results, prostate cancer, Prostate-Specific Membrane Antigen (PSMA), PSMA PET, 177Lu-PSMA-SPECT, biochemical recurrence (BCR), PROMISE, PRIMARY, PSMA_RADS, E-PSMA.
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…
Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector…
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC The Biological Basis of Metastatic Prostate Cancer – The Unmet Medical…
prostate cancer, Lymph Node-positive Prostate Cancer, androgen deprivation therapy (ADT), PSMA-PET/CT, cN1 disease, detection of lymph node metastasis, PSMA-PET/CT.
